News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
EFUND BIOPHAR (03186.HK) Debuts on HKEX, World's 1st Biopharma-Themed ETF Spanning HK & US Stock Mkts
E Fund Management (Hong Kong) announced that EFUND BIOPHAR (03186.HK) officially made its debut on HKEX (00388.HK) yesterday (23rd).This ETF is the world's first and currently ...
Reset
Send
The window will close in 5 seconds
EFUND BIOPHAR (03186.HK) Debuts on HKEX, World's 1st Biopharma-Themed ETF Spanning HK & US Stock Mkts
Close
Recommend
10
Positive
16
Negative
10
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

E Fund Management (Hong Kong) announced that EFUND BIOPHAR (03186.HK)  -0.010 (-0.061%)   officially made its debut on HKEX (00388.HK)  -4.400 (-1.099%)    Short selling $293.33M; Ratio 106.963%   yesterday (23rd).

This ETF is the world's first and currently the only biopharma-themed ETF spanning both the Hong Kong and US stock markets. It closely tracks the performance of the Solactive Biopharma Select Index, which has selected 100 constituent stocks from biopharmaceutical companies listed in Hong Kong and the US, covering global innovation hubs like China, the US, Europe, Israel, Switzerland, and Japan.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

Related News G Sachs Lowers TP for MSCI China Index and CSI 300 Index by 5% and 4%, Still Recommends Overweight on A Shares and H Shares

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.